HSM.TO
Helius Medical Technologies, Inc. [HSM.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
HSM.TO Stock Summary
In the News
HSM.TO Financial details
Company Rating
Sell
Market Cap
0
Income
-15.36M
Revenue
477K
Book val./share
3.61
Cash/share
3.2
Dividend
-
Dividend %
-
Employees
19
Optionable
No
Shortable
Yes
Earnings
17 May 2021
P/E
-1.16
Forward P/E
-
PEG
0.35
P/S
-
P/B
4.25
P/C
5.73
P/FCF
-
Quick Ratio
1.47
Current Ratio
1.93
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
-8.7
EPS next Y
-
EPS next Q
-
EPS this Y
-9.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-15.48%
EPS Q/Q
56.36%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-216%
ROE
-291%
ROC
-3.49%
Gross Margin
41%
Oper. Margin
-2176%
Profit Margin
-2138%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
18.35-18.48
52W High
+1.94%
52W Low
+1.94%
RSI
-
Rel Volume
1.26
Avg Volume
738
Volume
930
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.831877
-
-
Volatility
0%, 0%
Prev Close
0%
Price
18.35
Change
-
HSM.TO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2015-03-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| 2.01K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.73 | 1.99 | 0.55 | |
| Net income per share | -27.29 | -52.64 | -43.97 | -12.99 | -11.8 | |
| Operating cash flow per share | -19.39 | -36.3 | -30.14 | -27.89 | -9.8 | |
| Free cash flow per share | -19.39 | -36.66 | -30.81 | -28.36 | -9.86 | |
| Cash per share | 2.44 | 10.45 | 39.3 | 7.25 | 2.78 | |
| Book value per share | -4.79 | -14.07 | 15.14 | 7.75 | 3.23 | |
| Tangible book value per share | -4.79 | -14.07 | 15.14 | 5.33 | 2.16 | |
| Share holders equity per share | -4.79 | -14.07 | 15.14 | 7.75 | 3.23 | |
| Interest debt per share | 0.54 | 0 | 0 | 0.23 | 0.05 | |
| Market cap | 4.74M | 7.78M | 8.75M | 10.63M | 17.26M | |
| Enterprise value | 4.32M | 2.22M | -16.83M | 5.81M | 14.02M | |
| P/E ratio | -0.53 | -0.28 | -0.31 | -1.09 | -1.22 | |
| Price to sales ratio | 0 | 0 | 18.31 | 7.11 | 26.11 | |
| POCF ratio | -0.75 | -0.4 | -0.45 | -0.51 | -1.47 | |
| PFCF ratio | -0.75 | -0.4 | -0.44 | -0.5 | -1.46 | |
| P/B Ratio | -3.03 | -1.04 | 0.89 | 1.82 | 4.46 | |
| PTB ratio | -3.03 | -1.04 | 0.89 | 1.82 | 4.46 | |
| EV to sales | 0 | 0 | -35.21 | 3.88 | 21.21 | |
| Enterprise value over EBITDA | -0.5 | -0.08 | 0.59 | -0.61 | -1.03 | |
| EV to operating cash flow | -0.68 | -0.11 | 0.86 | -0.28 | -1.19 | |
| EV to free cash flow | -0.68 | -0.11 | 0.84 | -0.27 | -1.19 | |
| Earnings yield | -1.88 | -3.6 | -3.27 | -0.92 | -0.82 | |
| Free cash flow yield | -1.33 | -2.51 | -2.29 | -2.01 | -0.68 | |
| Debt to equity | 0 | 0 | 0 | 0.03 | 0.02 | |
| Debt to assets | 0 | 0 | 0 | 0.02 | 0.01 | |
| Net debt to EBITDA | 0.05 | 0.2 | 0.9 | 0.5 | 0.24 | |
| Current ratio | 1.02 | 0.46 | 1.5 | 1.9 | 1.93 | |
| Interest coverage | -50.23 | 0 | 0 | 0 | 0 | |
| Income quality | 0.71 | 0.69 | 0.69 | 2.15 | 0.83 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 36.01 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 20.79 | 5.39 | 6.93 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.18 | 0.2 | |
| Capex to operating cash flow | 0 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Capex to revenue | 0 | 0 | -0.92 | -0.24 | -0.11 | |
| Capex to depreciation | 0 | -11.18 | -7.46 | -1.85 | -0.15 | |
| Stock based compensation to revenue | 0 | 0 | 16.94 | 3.14 | 3.83 | |
| Graham number | 54.25 | 129.09 | 122.37 | 47.59 | 29.29 | |
| ROIC | 5.67 | 2.49 | -2.52 | -9.8 | -3.73 | |
| Return on tangible assets | -7.31 | -4.12 | -1.03 | -1.15 | -2.69 | |
| Graham Net | -6.06 | -15.42 | 12.31 | 2.23 | 0.85 | |
| Working capital | 18.54K | -7.68M | 8.99M | 3.44M | 2.26M | |
| Tangible asset value | -1.56M | -7.49M | 9.85M | 4.01M | 2.59M | |
| Net current asset value | -1.56M | -7.68M | 8.99M | 2.73M | 2.01M | |
| Invested capital | 0 | 0 | 0 | 0.03 | 0.02 | |
| Average receivables | 4.42K | 0 | 489.5K | 424.5K | 402K | |
| Average payables | 0 | 0 | 2.94M | 2.03M | 1.21M | |
| Average inventory | 0 | 0 | 196K | 495K | 493.5K | |
| Days sales outstanding | 0 | 0 | 209.99 | 140.05 | 127 | |
| Days payables outstanding | 0 | 0 | 0 | 723.1 | 702.72 | |
| Days of inventory on hand | 0 | 0 | 0 | 258 | 365.94 | |
| Receivables turnover | 0 | 0 | 1.74 | 2.61 | 2.87 | |
| Payables turnover | 0 | 0 | 0 | 0.5 | 0.52 | |
| Inventory turnover | 0 | 0 | 0 | 1.41 | 1 | |
| ROE | 5.69 | 3.74 | -2.9 | -1.68 | -3.65 | |
| Capex per share | 0 | -0.36 | -0.68 | -0.47 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
| Metric | History | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.11 | 0.1 | 0.13 | 0.04 | 0.03 | |
| Net income per share | -2.9 | -2.7 | -1.77 | -1.65 | -2.58 | |
| Operating cash flow per share | -2.78 | -2.01 | -1.52 | -1.43 | -1.63 | |
| Free cash flow per share | -2.78 | -2.02 | -1.55 | -1.44 | -1.63 | |
| Cash per share | 4.54 | 2.08 | 2.33 | 5.58 | 3.2 | |
| Book value per share | 5.51 | 2.48 | 2.71 | 5.83 | 3.61 | |
| Tangible book value per share | 4.35 | 1.47 | 1.81 | 5.22 | 3.08 | |
| Share holders equity per share | 5.51 | 2.48 | 2.71 | 5.83 | 3.61 | |
| Interest debt per share | 0.13 | 0.08 | 0.04 | 0.03 | 0.03 | |
| Market cap | 15.67M | 17.81M | 20.61M | 29.84M | 34.18M | |
| Enterprise value | 10.63M | 15.28M | 17.37M | 18.52M | 26.81M | |
| P/E ratio | -1.17 | -1.28 | -2.03 | -2.22 | -1.43 | |
| Price to sales ratio | 117.84 | 135.92 | 107.91 | 355.19 | 481.35 | |
| POCF ratio | -4.86 | -6.88 | -9.49 | -10.21 | -9.07 | |
| PFCF ratio | -4.86 | -6.85 | -9.28 | -10.14 | -9.07 | |
| P/B Ratio | 2.45 | 5.57 | 5.32 | 2.51 | 4.08 | |
| PTB ratio | 2.45 | 5.57 | 5.32 | 2.51 | 4.08 | |
| EV to sales | 79.89 | 116.64 | 90.95 | 220.43 | 377.64 | |
| Enterprise value over EBITDA | -3.28 | -4.52 | -7.14 | -5.68 | -4.53 | |
| EV to operating cash flow | -3.29 | -5.9 | -8 | -6.34 | -7.11 | |
| EV to free cash flow | -3.29 | -5.88 | -7.82 | -6.29 | -7.11 | |
| Earnings yield | -0.21 | -0.2 | -0.12 | -0.11 | -0.18 | |
| Free cash flow yield | -0.21 | -0.15 | -0.11 | -0.1 | -0.11 | |
| Debt to equity | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Debt to assets | 0.02 | 0.02 | 0.01 | 0 | 0.01 | |
| Net debt to EBITDA | 1.56 | 0.75 | 1.33 | 3.47 | 1.24 | |
| Current ratio | 3.33 | 1.61 | 1.93 | 5.08 | 4.2 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.96 | 0.74 | 0.86 | 0.87 | 0.63 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 9.83 | 10.13 | 4.33 | 15.67 | 19.39 | |
| Intangibles to total assets | 0.15 | 0.22 | 0.2 | 0.09 | 0.11 | |
| Capex to operating cash flow | 0 | 0 | 0.02 | 0.01 | 0 | |
| Capex to revenue | 0 | -0.08 | -0.26 | -0.25 | 0 | |
| Capex to depreciation | 0 | -0.11 | -0.48 | -0.21 | 0 | |
| Stock based compensation to revenue | 5.48 | 3.44 | 2.66 | 6.27 | 37.03 | |
| Graham number | 18.95 | 12.26 | 10.39 | 14.7 | 14.48 | |
| ROIC | -0.63 | -1.17 | -0.9 | -0.3 | -0.75 | |
| Return on tangible assets | -0.46 | -0.74 | -0.48 | -0.25 | -0.63 | |
| Graham Net | 2.92 | 0.23 | 0.71 | 4.42 | 2.37 | |
| Working capital | 4.72M | 1.57M | 2.26M | 10.33M | 6.85M | |
| Tangible asset value | 5.05M | 1.89M | 2.59M | 10.65M | 7.15M | |
| Net current asset value | 4.44M | 1.31M | 2.01M | 10.1M | 6.64M | |
| Invested capital | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Average receivables | 214K | 206K | 224K | 216.5K | 211.5K | |
| Average payables | 783.5K | 588K | 733.5K | 920K | 1M | |
| Average inventory | 582K | 571K | 480.5K | 436.5K | 495.5K | |
| Days sales outstanding | 131.28 | 149.77 | 108.38 | 217.5 | 278.87 | |
| Days payables outstanding | 641.25 | 2.95K | 334.48 | 6.56K | 1.23K | |
| Days of inventory on hand | 801.56 | 2.34K | 174.18 | 2.9K | 681.04 | |
| Receivables turnover | 0.69 | 0.6 | 0.83 | 0.41 | 0.32 | |
| Payables turnover | 0.14 | 0.03 | 0.27 | 0.01 | 0.07 | |
| Inventory turnover | 0.11 | 0.04 | 0.52 | 0.03 | 0.13 | |
| ROE | -0.53 | -1.09 | -0.65 | -0.28 | -0.71 | |
| Capex per share | 0 | -0.01 | -0.03 | -0.01 | 0 |
HSM.TO Frequently Asked Questions
What is Helius Medical Technologies, Inc. stock symbol ?
Helius Medical Technologies, Inc. is a US stock , located in Newtown of Pa and trading under the symbol HSM.TO
What is Helius Medical Technologies, Inc. stock quote today ?
Helius Medical Technologies, Inc. stock price is $18.35 today.
Is Helius Medical Technologies, Inc. stock public?
Yes, Helius Medical Technologies, Inc. is a publicly traded company.
Company Profile
- Volume Average 738
- Employee 19
- CEO Mr. Dane Carl Andreeff
- Headquarters Newtown,PA,US
- IPO Date 2016-04-18
-
Website
http://heliusmedical.com 
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator (PoNS), a medical device in Canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. Its PoNS device treats neurostimulation of cranial nerves via the tongue to restore lost function. The company is headquartered in Newtown, Pennsylvania.
